Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Senti Biosciences Inc. manages a distributed prosecution profile within the Biotechnology & Pharmaceuticals technology area. The company currently has 4 pending office actions, which are handled by 4 distinct examiners. This level of distribution suggests that the company is pursuing several different technical paths or distinct inventions. The portfolio spans 3 distinct art units, indicating that the subject matter is diverse enough to require review from multiple specialized units within the biotechnology sector. This diversity requires a prosecution strategy that can handle the nuances of different art unit standards.
The busiest examiner for Senti Biosciences Inc. is SZPERKA, MICHAEL EDWARD, who is responsible for 1 busiest examiner pending action. Because there are 4 pending office actions and 4 distinct examiners, no single individual dominates the company's workload. This spread across 3 distinct art units and 4 distinct examiners may provide a more balanced prosecution experience by avoiding over-reliance on a single reviewer. Practitioners must be prepared to address the varied technical requirements and examination styles of four different individuals across these multiple units. The distribution of 4 pending actions across 4 distinct examiners highlights a broad engagement with the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
| LEE, JAE W | 1 | 65.6% | +38.5% |
| SHUPE, ELIZABETH A | 1 | 65.8% | +45.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18352079 | SECRETABLE PAYLOAD REGULATION | LEE, JAE W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18504037 | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF | SZPERKA, MICHAEL EDWARD | — |
| 18352079 | SECRETABLE PAYLOAD REGULATION | LEE, JAE W | — |
| 18199154 | INDUCIBLE CELL DEATH SYSTEMS | SHUPE, ELIZABETH A | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1656 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18504037 | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF | SZPERKA, MICHAEL EDWARD | 1641 | §112DP | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18352079 | SECRETABLE PAYLOAD REGULATION | LEE, JAE W | 1656 | §103§112 | Non-Final OA | — | Pending | Jul 13, 2023 |
| 18199154 | INDUCIBLE CELL DEATH SYSTEMS | SHUPE, ELIZABETH A | 1643 | §102§103§112DP | Non-Final OA | — | Pending | May 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSenti Biosciences Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Michael Edward Szperka has the most, with 1 of Senti Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
